Please login to the form below

Not currently logged in
Email:
Password:

Hutchison MediPharma

This page shows the latest Hutchison MediPharma news and features for those working in and with pharma, biotech and healthcare.

Lilly enters cancer collaboration in China

Lilly enters cancer collaboration in China

Lilly will work with Chi-Med's research-focused subsidiary Hutchison MediPharma to investigate fruquintinib (HMPL-013), a small molecule to inhibit the vascular endothelial growth factor (VEGF) receptor tyrosine kinases. ... Both companies will share

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. † Hutchison MediPharma / Eli Lilly.

  • Pharma deals during October 2013 Pharma deals during October 2013

    Focusing on China, Lilly has entered into a licence and co-development agreement with Hutchison MediPharm a for fruquintinib (HMPL-013), a phase II inhibitor of all three forms of Vascular ... Hutchison MediPharma will continue the development of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics